ArticleFrontiers in cellular and infection microbiology2024
Evaluation of nucleotide MALDI-TOF-MS for the identification of
Article in Frontiers in cellular and infection microbiology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 2 syntheses or guidelines pooled it, 15 citations in OpenAlex.
- Comparative evaluation of molecular technologies for the identification of prevalent non-tuberculous mycobacteria in pulmonary infections: a systematic review and meta-analysis.Annals of medicine · 2026Pooled it
- Prevalence of non-tuberculous mycobacteria in various regions of the Russian Federation.BMC infectious diseases · 2026Pooled it
- Diagnostic performance of nucleic acid MALDI-TOF MS in mycobacterial detection, species identification, and drug resistance testing for Mycobacterium tuberculosis.BMC infectious diseases · 2026Article
- Applications and technical challenges of MALDI mass spectrometry imaging in microbial ecosystems and metabolic network research.Archives of microbiology · 2026Review
- DisseminatedJournal of clinical tuberculosis and other mycobacterial diseases · 2026Article
- Direct identification of Mycobacterium species from liquid medium (MGIT) using FastPrep-2 bead beating system and MALDI-TOF mass spectrometry technology: a comparison with solid media and PCR-based method.Practical laboratory medicine · 2025Article
- The growing impact of nontuberculous mycobacteria: A multidisciplinary review of ecology, pathogenesis, diagnosis, and treatment.Infectious medicine · 2025Review
- Differentiating Nontuberculous Mycobacterial Pulmonary Disease from Pulmonary Tuberculosis in Resource-Limited Settings: A Pragmatic Model for Reducing Misguided Antitubercular Treatment.Healthcare (Basel, Switzerland) · 2025Article
- Diagnostic Performance of Nucleotide MALDI-TOF-MS for the Rapid Diagnosis of Pulmonary Tuberculosis and the Detection of Drug Resistance.Infection and drug resistance · 2025Article
- Comparative evaluation of MALDI-ToF mass spectrometry and Sanger sequencing of theFrontiers in cellular and infection microbiology · 2025Article
- Comparison of Nucleotide MALDI-TOF MS with Xpert MTB/RIF for Rifampicin Susceptibility Identification and Associated Risk Factors of Rifampicin Resistance Among Drug ResistantInfection and drug resistance · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The accurate identification of the Methods: A total of 933 clinical Results: The total correct detection rate of all 933 clinical Conclusion: In conclusion, nucleotide MALDI-TOF-MS is a promising approach for identifying MTBC and the most common clinical NTM species.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.